narmac
It does not make sense for KD to take this company on. In order to capitalize on a block buster drug you need to have in place an effecient distribution network. This takes years to develope. You are so correct in saying that KD is a smart guy and he knows full well that he and we will make many fold more by selling RVX208 to a pharma with in place distribution. Look at the slides 35 and 36 in todays presentation, 7 years to reach 64% market penitration. Try doing that from scratch and it would take you 15 years and your patent is only good for 13 years once the drug hits the market in 2021. KD is no fool.
Speaking of slides 35 and 36 I didn't notice during the AGM the New Pricing Model that is commented on on the bottom of slide 35. When you update the numbers used to calculate the NPV on slide 36 it more than doubles the NPV and suggeststhat, if the moon and stars line up that the NPV would be in the $15 to $16 billion dollar area. I like those numbers with 120 million shares outstanding.
Have a great day
tada
